

RECEIVED

JUN 11 2001

TECH CENTER 1600 2900

1636 11/13
Box 500
Dkt. 0575/60849/JPW/APE



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Paul B. Fisher, et al.

Serial No.: 09/515,363 Examiner: B. Loeb

Filed : February 29, 2000 Art Unit: 1636

For : MELANOMA DIFFERENTIATION ASSOCIATED GENE-5
(Mda-5), PROMOTER AND USES THEREOF

1185 Avenue of the Americas
New York, New York 10036
June 1, 2001

Assistant Commissioner for Patents
Washington, D.C. 20231

SIR:

**AMENDMENT IN
RESPONSE TO THE MAY 4, 2001
COMMUNICATION REGARDING SEQUENCE LISTING AND DISCLOSURES**

This Amendment is submitted in response to the May 4, 2001 Communication and Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures issued by the United States Patent and Trademark Office in connection with the above-identified application. A copy of the Notice is attached hereto as **Exhibit A**. A response to the May 4, 2001 Notice is due June 4, 2001. Accordingly, this Amendment is being timely filed.

Please amend the specification as follows:

In the Specification

Please insert after page 84, the paper copy of the "Sequence Listing", pages 1-14, attached hereto as **Exhibit B**.

Sequence Listing

The Examiner stated that the Communication filed April 3, 2001

Applicants: Paul B. Fisher, et al.
Serial No.: 09/515,363
Page 2

was not fully responsive to the Office communication mailed March 6, 2001 because of format errors found in the submitted diskette.

In response, applicants submit herewith a substitute computer readable form (C.R.F.) of the "Sequence listing" in ASCII (DOS) format on the enclosed computer diskette.

Applicants submit herewith a paper copy of the Sequence Listing, attached herewith as **Exhibit B**, and a Statement of Compliance Under 37 C.F.R. §1.821(f) attached hereto as **Exhibit C**, certifying that the computer readable form as required by 37 C.F.R. §1.821(e) is identical to the paper copy of the Sequence Listing attached as **Exhibit B**. Applicants believe that the enclosed C.R.F., paper copy of the Sequence Listing (**Exhibit B**) and Statement of Compliance Under 37 C.F.R. §1.821(f)) (**Exhibit C**) now fully complies with the requirements of 37 C.F.R. §1.821 through 37 C.F.R. §1.825.

If a telephone interview would be of assistance in advancing prosecution of the subject application, applicants' undersigned attorney invite the Examiner to telephone at the number provided below.

Applicants: Paul B. Fisher, et al.
Serial No.: 09/515,363
Page 3



RECEIVED
JUN 11 2001
TECH CENTER 1600
1600 2300

No fee is deemed necessary in connection with the filing of this Amendment. However, if any other fee is required, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 03-3125.

Respectfully submitted,

John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

I hereby certify that this correspondence is being deposited this date with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to:

Assistant Commissioner for Patents
Washington, D.C. 20231.

John P. White
Reg. No. 28,678

Date
6/11/01